| Ms Megan Paige Dotson, | |
|
655 Denbigh Blvd Newport News, Morning Side Of Newport News, Newport News, VA 23608 | |
| (757) 890-0905 | |
| Not Available |
| Full Name | Ms Megan Paige Dotson |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapy |
| Experience | 12 Years |
| Location | 655 Denbigh Blvd Newport News, Newport News, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366888042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 0119005976 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fox Rehabilitation Services Llc | 1355347410 | 258 |
News Archive
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
› Verified 2 days ago
| Provider Name | Fox Rehabilitation Services Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1609814755 PECOS PAC ID: 1355347410 Enrollment ID: O20091019000338 |
News Archive
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
› Verified 2 days ago
| Provider Name | Old Dominion University |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1871929729 PECOS PAC ID: 3476770520 Enrollment ID: O20140813001294 |
News Archive
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Megan Paige Dotson, 200 College Place, Apt 204, Norfolk, VA 23510 Ph: (304) 784-2256 | Ms Megan Paige Dotson, 655 Denbigh Blvd Newport News, Morning Side Of Newport News, Newport News, VA 23608 Ph: (757) 890-0905 |
News Archive
According to the Centers for Disease Control and Prevention, 300 million people across the globe are unaware they're living with viral hepatitis. In fact, baby boomers-;those born between 1945-1965-;are five times more likely to have hepatitis C, one of the many different strains of this viral infection.
Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that the first patient has now been randomized and will begin dosing in the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.
Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.
New research shows that treating people with first episode psychosis with a team-based, coordinated specialty care approach produces better clinical and functional outcomes than typical community care. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.
When remote regions with limited health facilities experience an epidemic, they need portable diagnostic equipment that functions outside the hospital. As demand for such equipment grows, EPFL researchers have developed a low-cost and portable microfluidic diagnostic device. It has been tested on Ebola and can be used to detect many other diseases.
› Verified 2 days ago
Martavius Collins, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 704 City Center Blvd, Newport News, VA 23606 Phone: 757-595-4880 | |
Nancy Milroy, OTD Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11832 Rock Landing Dr #105, Newport News, VA 23606 Phone: 757-455-5000 | |
Emma Martone, Occupational Therapist Medicare: Medicare Enrolled Practice Location: 11832 Rock Landing Dr, Newport News, VA 23606 Phone: 757-455-5000 | |
Sarah Clark, MOT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 41 Old Oyster Point Rd Ste E, Newport News, VA 23602 Phone: 757-223-1466 Fax: 757-233-1467 | |
Kelcie Richburg, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 729 Thimble Shoals Blvd Ste 5-c1, Newport News, VA 23606 Phone: 757-863-9183 | |
Mrs. Phyllis R Ross, OTR/L, CHT, CLT Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 11712 Jefferson Ave, Suite D, Newport News, VA 23606 Phone: 757-595-4880 Fax: 757-595-4886 | |
Mrs. Angela Marie Fitzgerald, MS, OTR, CHT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 11848 Rock Landing Dr, Suite 303, Newport News, VA 23606 Phone: 757-873-8839 Fax: 757-873-1142 |